Unknown

Dataset Information

0

BioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA).


ABSTRACT: Targeted degradation approaches such as proteolysis targeting chimeras (PROTACs) offer new ways to address disease through tackling challenging targets and with greater potency, efficacy, and specificity over traditional approaches. However, identification of high-affinity ligands to serve as PROTAC starting points remains challenging. As a complementary approach, we describe a class of molecules termed biological PROTACs (bioPROTACs)-engineered intracellular proteins consisting of a target-binding domain directly fused to an E3 ubiquitin ligase. Using GFP-tagged proteins as model substrates, we show that there is considerable flexibility in both the choice of substrate binders (binding positions, scaffold-class) and the E3 ligases. We then identified a highly effective bioPROTAC against an oncology target, proliferating cell nuclear antigen (PCNA) to elicit rapid and robust PCNA degradation and associated effects on DNA synthesis and cell cycle progression. Overall, bioPROTACs are powerful tools for interrogating degradation approaches, target biology, and potentially for making therapeutic impacts.

SUBMITTER: Lim S 

PROVIDER: S-EPMC7084165 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA).

Lim Shuhui S   Khoo Regina R   Peh Khong Ming KM   Teo Jinkai J   Chang Shih Chieh SC   Ng Simon S   Beilhartz Greg L GL   Melnyk Roman A RA   Johannes Charles W CW   Brown Christopher J CJ   Lane David P DP   Henry Brian B   Partridge Anthony W AW  

Proceedings of the National Academy of Sciences of the United States of America 20200302 11


Targeted degradation approaches such as proteolysis targeting chimeras (PROTACs) offer new ways to address disease through tackling challenging targets and with greater potency, efficacy, and specificity over traditional approaches. However, identification of high-affinity ligands to serve as PROTAC starting points remains challenging. As a complementary approach, we describe a class of molecules termed biological PROTACs (bioPROTACs)-engineered intracellular proteins consisting of a target-bind  ...[more]

Similar Datasets

| S-EPMC3491057 | biostudies-literature
| S-EPMC2674943 | biostudies-literature
| S-EPMC3493961 | biostudies-literature
| S-EPMC5893992 | biostudies-literature
| S-EPMC3033280 | biostudies-literature
| S-EPMC3091797 | biostudies-literature
| S-EPMC9168989 | biostudies-literature
| S-EPMC2781439 | biostudies-literature
| S-EPMC4509624 | biostudies-literature
| S-EPMC3041752 | biostudies-literature